Patent · US Active

Compounds, compositions, and methods

US11591316B2 · kind B2 · utility

1Cited by
7References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 13, 2021
Grant dateFeb 28, 2023
Priority date—
Expiry dateAug 13, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/05
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.